Navigation Links
Herpes virus: To vaccinate or not to vaccinate
Date:2/12/2009

Saranac Lake, N.Y., February 12, 2009--Dr. Marcia Blackman and her research team at the Trudeau Institute have followed up on an intriguing report published in the journal Nature in May 2007 by Dr. Herbert Virgin, et al., showing that mice persistently infected with certain forms of herpesvirus, which can establish lifelong latent infections, are resistant to infection with bacterial pathogens.

Although herpesvirus infections are generally considered undesirable and can be associated with declining immune function in the elderly or the development of a variety of tumors later in life, the Virgin report raised the unexpected possibility that they may also be beneficial.

Dr. Blackman's research has now confirmed Dr. Virgin's findings, but with some further refinements about herpes' roles in preventing other infections: "We discovered that the effect of herpesvirus infection is transient, lasting only a few months. Interestingly, although the effect was shown by the Virgin group to be dependent on establishing a latent infection, it wanes despite lifelong latency."

Recognizing that her data had implications for the interpretation of Dr. Virgin's data, Dr. Blackman shared her findings with the Virgin group prior to publication. This led to an interesting exchange between the two labs in the form of letters to the editor regarding the potential benefits of a transient protective effect. The letters will be published concurrently with Blackman's data in the February issue of Viral Immunology (Vol. 22, No.1). The scientists agree that even short-acting protection, especially during childhood, might have long-lasting implications in terms of survival rates.

A major point of discussion between the two groups concerned the implications of such research for the development of vaccines against herpesvirus infections. Dr. Virgin suggested that "decreased infection may be associated with unintended negative consequences for vaccinated individuals." In response, Dr. Blackman argues that possible transient protective effects did not outweigh the already recognized pathological consequences of herpesvirus infection. Both groups agreed that the protective effects of herpesvirus infections merit further study.

Importantly, both groups hope their observations will stimulate epidemiological and clinical studies to determine whether herpesvirus infections really protect humans against bacterial diseases.


'/>"/>

Contact: Brian Turner
bturner@trudeauinstitute.org
518-891-3080
Trudeau Institute
Source:Eurekalert  

Related biology news :

1. Penn researchers shine the light of venus to learn how the herpes virus invades cells
2. Herpes virus link to complications in pregnancy
3. Herpes drug inhibits HIV in patients infected with both viruses
4. Potential new herpes therapy studied
5. Prostate cancer: Watchful wait or vaccinate?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Herpes virus: To vaccinate or not to vaccinate
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
Breaking Biology News(10 mins):
(Date:6/22/2016)... NEW YORK , June 22, 2016 /PRNewswire/ ... the growing next generation sequencing (NGS) market include ... adoption of smaller sequencers.  More accessible and affordable ... led to growing demand for consumables including sample ... The Market for Sample Preparation for Next ...
(Date:6/22/2016)... , June 22, 2016   ViaCyte, Inc. , ... stem cell-derived islet replacement therapy for the treatment of ... ISSCR 2016 Annual Meeting.  ISSCR 2016, the Global Stem ... at Moscone West in San Francisco.  ... presentations are as follows:Event: , Focus Session: Tools for ...
(Date:6/22/2016)... 2016  Mesa Biotech Inc., a privately-held, molecular ... designed specifically for point-of-care (POC) infectious disease diagnosis, ... board (SAB). Approved by the executive leadership team ... to advise on the development and commercialization of ... Dr. Steve Young , this world-class team ...
(Date:6/21/2016)... NANJING , China , June ... that a Phase 2 clinical trial for its novel ... statistically significant (p=0.023) and clinically meaningful pain relief against ... the United States , the trial enrolled 146 ... statistically significant (1) analgesia against placebo at week-1 (p=0.024), ...
Breaking Biology Technology: